Deletion of *Vhl* in *Dmp1*-expressing cells causes microenvironmental impairment of B cell lymphopoiesis

Betsabel Chicana^{1,2}, Nastaran Abbasizadeh^{2,3}, Christian Burns^{2,3}, Hanna Taglinao¹, Joel A. Spencer^{2,3,4†*}, Jennifer O. Manilay^{1,2†*}

¹Department of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, Merced, CA, USA, ²Quantitative and Systems Biology Graduate Program, University of California, Merced, Merced, CA, USA, ³Department of Bioengineering, School of Engineering, University of California, Merced, Merced, CA, USA, ⁴Bioengineering Graduate Program, University of California, Merced, Merced, CA, USA.

† Joint Senior Authors (J.A.S and J.O.M)

***Correspondence to joel.spencer@ucmerced.edu (J.A.S.) and jmanilay@ucmerced.edu (J.O.M.)**

ABSTRACT

The contributions of skeletal cells to the processes of B cell development in the bone marrow (BM) have not been completely described. The von-Hippel Lindau protein (VHL) plays a key role in cellular responses to hypoxia. Previous work showed that *Dmpl-Cre;Vhl* conditional knockout mice (*VhlcKO*), which delete *Vhl* in late osteoblasts and osteocytes, display dysregulated bone growth and reduction in B cells. Here, we investigated the mechanisms underlying the B cell defects using flow cytometry and high-resolution imaging. In the *VhlcKO* BM, B cell progenitors were increased in frequency and number, whereas Hardy Fractions B-F were decreased. *VhlcKO* Fractions B-C cells showed increased apoptosis and quiescence. Reciprocal BM chimeras confirmed a B cell-extrinsic source of the *VhlcKO* B cell defects. In support of this, *VhlcKO* BM serum contained reduced CXCL12 and elevated EPO levels. Staining of *VhlcKO* B cells with an intracellular hypoxic marker indicated the natural existence of distinct B cell microenvironments that differ in local oxygen tensions. Additionally, intravital and ex vivo imaging revealed *VhlcKO* BM blood vessels with increased diameter, frequency, volume, and a diminished blood-BM barrier. Our studies identify novel mechanisms linking altered bone homeostasis with drastic BM microenvironmental changes that dysregulate B cell development.

INTRODUCTION

The mechanisms by which changes in bone homeostasis affect immune development in the bone marrow (BM) are not fully understood (1-4). A detailed understanding of how bone microenvironments affect immune cell development and function could provide strategies towards novel therapeutic approaches to immune deficiencies. B cells produce antibodies (Abs), which are crucial for a robust adaptive immune response. B cells are generated from hematopoietic stem cells (HSCs) in the liver during fetal life, and in the BM in the adult (5). B cell development in the BM occurs in a series of defined stages that rely on growth factors that are produced by osteolineage derived cells in the BM microenvironment, such as mesenchymal stem cells (MSCs) and osteoblasts (OBs) (1).

The von-Hippel Lindau protein (VHL) regulates hypoxia-inducible factor (HIF) degradation, which is involved in cellular adaptation to low oxygen environments (6). When HIF1 α accumulates in normoxic conditions, it travels to the nucleus to activate over 100 hypoxia-inducible target genes (7). VHL is expressed ubiquitously in many cell types, and global deletion of the *Vhl* gene results in embryonic lethality, so conditional knockout approaches are necessary to investigate the cell-specific roles of VHL in specific microenvironments. Conditional-deletion of *Vhl* in OBs and in hematopoietic progenitors have demonstrated a role for VHL in these cell types (8, 9). OBs support B cell development, and also mature into osteocytes (OCYs). The role of HIF and its regulation on the immune system has been extensively reviewed, but the mechanism of cell-intrinsic and cell-extrinsic VHL on specific immune cell lineages has not fully been addressed (10).

The BM microenvironment manifests hypoxic heterogeneities in a spatio-temporal manner (11), however the implications of these oxygen tension (pO₂) differences on hematopoiesis are not

well characterized. Hypoxia slows the processes of angiogenesis and osteogenesis during fracture healing and bone formation, but also promotes OB differentiation into OCYs (12), and can stimulate osteoclast formation (13). Studies have shown HIF stabilization as a therapeutic option for treating bone fractures (14, 15) and osteoporosis (16-18), but the underlying molecular mechanism remains poorly understood. VHL plays an important role regulating HIF expression, and disruption of VHL in bone cells leads to improper bone homeostasis. VHL depletion in osteochondral progenitor cells and osteocalcin-positive OBs leads to an increase in bone mass through an increase in OB number (7, 19). Furthermore, disrupting VHL in OBs induces expression of β -catenin, revealing the mechanism by which VHL/HIF pathway promotes bone formation through the Wnt pathway (7, 20, 21). Altogether, these studies of *Vhl* deletion in osteolineage cells have not examined the cell-extrinsic effects of these changes on the immune cells residing in the BM.

The BM contains specialized microenvironments that maintain blood cells and supply factors required for their development and maintenance. Perivascular stromal cells, osteoprogenitor cells, endothelial cells (ECs), MSCs, OBs and OCYs are critical B cell “niches” and are all cells that support B cell development. Collectively, these cells provide essential cytokines for B cell development which include CXC-chemokine ligand 12 (CXCL12), FLT3 ligand (FLT3L), IL-7, stem-cell factor (SCF) and receptor activator of nuclear factor- κ B ligand (RANKL) (1, 22-31). Development of B cells starts at the pre-pro-B cell (Fraction A) stage where they are near OBs and CXCL12⁺ reticular cells, and as B cells continue to mature to the pro-B cell stage (Fractions B-C), they move closer to IL-7 expressing cells; the CXCL12/IL7 levels in the niche is crucial to sustain B cell development (4, 27-29, 31, 32). Furthermore, the BM contains a dense vascular network and vascular sinuses creating the perivascular region, which provides a

niche where B cells are known to develop and reside (33). During aging, vascular density decreases in many tissues due to impaired angiogenesis caused by EC dysfunction. Vascular “hyperpermeability” also increases with age, via changes in ECs lining the blood vessel wall, disrupting the blood-BM barrier (34-36). The role of the vasculature and regulation of vessel permeability in hematopoiesis, especially in B cell development, remains unknown.

To understand how changes in bone homeostasis may affect immune cell development, our laboratories utilized *Dmpl-Cre;Vhl* conditional knockout mice (*Vhl*CKO), in which *Vhl* is deleted primarily in late OBs and OCYs. In the *Vhl*CKO bones, the number of hematopoietic cells is severely reduced, and B cell development is stunted (37). Here, we provide evidence for molecular, cellular and structural changes in the *Vhl*CKO BM niche that adversely affect B cell development in a cell-extrinsic manner, such as reduction in key niche cells, decreased production of B cell supporting cytokines, and structural changes in the BM vasculature. These studies reveal novel molecular mechanisms by which *Vhl* deletion in *Dmpl*-expressing cells affect B cell niches.

MATERIALS AND METHODS

Study design

A G*Power statistical (38) power analysis ($\alpha=0.05$ and power of 0.95) based on B cell developmental data and BM cellularity determined that a minimum of $n=7$ mice per group was needed for our studies. The total sample size for each experiment was >7 performed in three independent experiments. Age-matched mice of both sexes *Vhl*KO and control mice (C57BL/6 wild type and *Vhl*-floxed (*Vhl*^{fl/fl}, *Dmp1*-Cre-negative mice) were used and no sex-specific differences in B cell development or other relevant characteristics to our studies were detected. Student's t-test and nonparametric Bonferroni-corrected Mann-Whitney U-test was used to test differences between mean and median values with Graph-Pad Prism and were considered significant if $p<0.05$.

Experimental Animals

Mice on the C57Bl/6 background were used. B6N.FVB-Tg1Jqfe/BwdJ (*Dmp1*-Cre) (39) and B6.129S4(C)-Vhl tm1Jae/J (*Vhl*^{fl/fl}) (40) were purchased from The Jackson Laboratory. These two lines of mice were crossed to generate *Vhl* conditional knockouts in *Dmp1*-expressing cells (*Vhl*KO). Genotyping was confirmed following protocols from Jackson Laboratory for JAX Stock #021047 and #012933. Mice were housed under specific pathogen-free conditions in the University of California, Merced's vivarium with autoclaved feed and water, and sterile microisolator cages. The University of California Merced Institutional Animal Care and Use Committee approved all animal work.

Bone marrow transplantation

Recipient mice were 10 weeks of age at the time of transplantation. Whole bone marrow WT (CD45.1+) donor cells (1×10^6) were injected retro-orbitally into lethally irradiated (1000 rads using a Cesium-137 source, JL Shepherd and Associates, San Fernando, CA, USA) recipient *VhlcKO* (CD45.2+) mice under isoflurane anesthesia. Reciprocal *VhlcKO*→WT chimeras were also prepared. Animals were supplemented with neomycin in the drinking water for 14 days post-transplant as described (41).

Sample Collection: Bone Marrow, Peripheral Blood, Spleen and Serum

Bone marrow collection

Mice were euthanized by the inhalation of carbon dioxide followed by cervical dislocation. Femurs and tibias were dissected, and muscles were removed. To release the BM, bones were crushed with a mortar and pestle in M199+ (M199 with 2% FBS). BM cells were collected into 15mL conical tubes after being rinsed away from bone chips with M199+, resuspended by trituration, filtered through 70-micron nylon mesh into a 50 mL conical tube, and centrifuged for 5 mins at 1500 rpm and at 4°C. Cell pellets were resuspended and treated with ACK lysis buffer to remove erythrocytes. Cells treated with ACK were washed and resuspended in M199+. Cell counts were obtained using a hemocytometer and Trypan Blue staining to exclude dead cells.

To collect BM serum, femurs were cleaned of any muscle tissue and the epiphyses were cut off and discarded. The bone shaft was then placed into a 0.2 mL tube in which a hole was introduced using a needle. Thirty μ L of 1x phosphate buffered saline (PBS) was placed on the top end of the bone shaft, using a 25g needle, and then the tube containing the bone was placed into a

1.5 ml microcentrifuge tube and centrifuged for 30 seconds at 15,000rpm. Serum supernatant was collected and stored at -80C until analysis.

Peripheral blood collection

Mice were heated under a heat lamp to increase blood circulation and then restrained. Blood collection was performed via tail bleeds by making an incision with a scalpel blade over the ventral tail vein. No more than ten drops were collected (<0.5 mL) in a 1.5 ml Eppendorf tube with 50 uL of heparin. To obtain blood serum, blood was collected in 1.5 ml tubes without heparin and allowed to clot for 30 minutes at room temperature. The samples were then centrifuged for 10 minutes at 4000 rpm at 4°C. Blood serum was collected and stored at -80°C until the day of analysis.

Spleen cell collection

Dissected spleens were processed and mashed in 1 mL of ACK lysis buffer in a petri dish for no more than one minute. Five mL of M199+ were added into the dish to dilute the ACK lysis buffer and to stop red cell lysis. Spleen cells were aspirated into a 5mL syringe to create single cell suspensions by passing the cells through the syringe several times then filtering through a 70-micron nylon mesh into a 15 mL conical tube. Cells were centrifuged at 2000 rpm at 4°C for 3 minutes. Cell pellets were finger vortexed and resuspended with 5 mL of M199+. Live cell counts were determined using a hemocytometer and Trypan Blue staining.

Quantification of cytokines

Cytokine measurements were performed using a customized bead-based multiplex (13-LEGENDplex assay) from Biolegend, Inc. with the analytes IL-3, IL-5, IL-6, IL-7, IL-15, IL-34, M-CSF, TPO, GM-CSF, LIF, EPO, CXCL12, SCF for the analysis of BM serum and peripheral

blood serum of *VhlcKO* and control mice. Concentrations of cytokines were determined from samples following manufacturer's instructions and software.

Flow cytometry analysis and antibodies

Cells were stained for flow cytometry and included a pre-incubation step with unconjugated anti-CD16/32 (clone 93) to block Fc receptors as previously described (41, 42). Samples were stained with antibodies listed in **Supplemental Table 1**. For viability staining, DAPI or PI was used. Single color stains were used for setting compensations and gates were determined with fluorescent-minus one controls, isotype-matched antibody controls, or historical controls. Intracellular staining of Ki67 was performed using the eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set following the manufacturer's instructions. Apoptosis staining was performed using Biolegend Annexin V Apoptosis Detection Kit with 7AAD. Flow cytometry data was acquired on the BD LSR II. The data was analyzed using FlowJo Software version 10.7.1.

Preparation of long bones for imaging

To label blood vessels, mice were injected with fluorescent antibodies (**Supplemental Table 1**) through the retro-orbital venous sinus. After 20 minutes of incubation, intracardial perfusion was performed with 1X PBS following by cold and fresh 4% paraformaldehyde (PFA). Subsequently, femurs were harvested and fixed in the 4% PFA for 30 minutes, at 4° C. The bones were then washed with 1X PBS, immersed in 30% sucrose for 1 hour, frozen in optimal cutting temperature (OCT) compound and kept at – 80° C. Samples were shaved using a cryostat (LEICA CM1860) equipped with a high-profile blade (Leica; 3802121).

To optically clear long bones, a modified uDISCO clearing protocol was used (43). After intracardial perfusion as described above, long bones were immersed in 4% PFA overnight and put through a series of *tert*-butanol dehydration steps at 30% (4 hours), 50% (4 hours), 70% (overnight), 80% (4 hours), 90% (4 hours), and 100% (overnight). Next, long bones were incubated in dichloromethane (DCM) for 40 minutes and then placed in Benzyl Alcohol Benzyl Benzoate - DL-alpha-tocopherol (BABB-D4) for 3-4 hours. BABB-D4 is prepared by mixing Benzyl Alcohol + Benzyl Benzoate at the ratio of 1:2, adding diphenyl ether (DPE) to the BABB solution (1:4) and ultimately DL-alpha-tocopherol (Vitamin E) with the ratio of 1:25 to decrease fluorescence quenching. Cleared femurs were mounted in a custom glass chamber filled with BABB-D4 and sealed with solvent-resistant silicone gel (DOWSIL™ 730) (43).

Two-photon microscopy

Imaging was performed with a custom-built two-photon video-rate microscope (Bliq Photonics) equipped with two femtosecond lasers (Spectra Physics; Insight X3, Spectra Physics; MaiTai eHP DS). During intravital imaging, the Spectra Physics Insight X3 and Maitai laser wavelengths were tuned to 840 nm and 1040 nm, respectively, and for ex vivo imaging only the Insight X3 was tuned to 1220 nm. Three fluorescent channels were acquired (520-535 nm, 590-636 nm, and 679-741 nm). For all two-photon imaging, a 25x water immersion objective (Olympus; XLPLN25XWMP2) with 1.05 numerical aperture was used to image a 317 µm by 159 µm field of view. Videos were recorded at 30 frames per second and images were generated by averaging of 30 frames from the live video mode.

For in vivo imaging of calvarial bone marrow, mice were anesthetized with isoflurane (3-4% induction, 1.5% maintenance at 1L/min) and the top of the head shaved. The skin was cleaned

with 70% alcohol wipes before surgery. The mouse was placed on a heating pad and secured in a custom head mount. An incision was made along the sagittal and lambda suture of the skull and the skin retracted to expose the calvarial bone as previously described (11, 44). The secured mouse was then placed on the microscope stage for two-photon microscopy(11, 44). In order to measure BM blood vessel permeability, leakage and flow velocity in the calvaria BM during in vivo imaging, 70 kDa Rhodamine-B-Dextran (ThermoFisher; D1841) was injected retro-orbitally while the mouse was on the stage.

For ex vivo imaging, optically cleared long bones were mounted in a chamber sealed with solvent-resistant silicone gel and shaved long bones were mounted on a wet sponge to prevent the sample from drying during imaging. Slides were imaged with similar acquisitions settings as the in vivo imaging.

Image quantification

For in vivo image analysis, image processing and permeability/leakage measurements were performed with Fiji (ImageJ 1.53k) and BM blood flow velocity was quantified with custom scripts in MATLAB (2020a). To measure permeability in the calvaria, live two-photon microscopy video was recorded for the first 30 seconds after Rhodamine B Dextran was injected. The blood vessel permeability was calculated based on the change in fluorescence intensity outside of blood vessels over time as previously described (45, 46). For leakage measurements, z-stacks (2 μm step size) were recorded randomly around the calvarium BM 10 minutes after injection. Leakage values were calculated by dividing the fluorescence intensity of the perivascular space adjacent to a vessel by the fluorescence intensity inside the blood vessel. Representative examples of BM leakage were generated by taking maximum intensity projections (MIPs) of BM regions with image

contrast/enhancement applied. Blood flow velocity was calculated by recording 30 second videos of blood flow in the BM calvaria and then utilizing the Line Scanning Particle Image Velocimetry (LSPIV) method implemented in a custom MATLAB script to calculate blood flow velocity as previously described (47, 48). ImageJ (ImageJ 1.53k) was used to adjust video and image contrast for figure presentation.

To generate a depth-dependent profile of vessel diameter in long bones, measurements were taken at 0-30 μm (shallow BM), 75-105 μm (middle BM), and 150-180 μm (deep BM) below the endosteum. To measure vascular density, image brightness/contrast was first adjusted in Fiji (ImageJ 1.53k) and then images were converted to binary. Next, noise reduction was performed via Despeckle, and binary Fill Hole was applied. Finally, using analytical coding developed in Python (3.7.6), the ratio of the total blood vessel pixels to total BM pixels was determined for BM vessel density measurements.

RESULTS

Vhl deletion in Dmp1-expressing cells dysregulates hematopoiesis

Long bones in *Vhl*KO mice display abnormally high bone mass and density and the BM cavity is severely occluded with bone, accompanied by stunted B cell development (37) (**Figure 1A**). Consistent with this, *Vhl*KO mice displayed splenomegaly, consistent with extramedullary hematopoiesis (**Supplemental Figure 1A-E**). *Vhl*KO mice exhibit reduced BM cellularity compared to controls (**Figure 1B**) and analysis of specific hematopoietic cell lineages revealed a decrease in B cells, no change in T cell frequency, and an increase in monocytes and granulocytes in 6-week-old, 10-week-old and 6-month-old mice (**Figure 1C-D**). Similarly, lineage analysis in the spleen at 10 weeks revealed a decrease in B cells, no change in T cells, and an increase in granulocytes that became more prominent as mice aged to 6-months. Monocytes in the *Vhl*KO spleen at 6-weeks-old were slightly reduced, similar to controls at 10-weeks-old, and were increased at 6-months-old (**Supplemental Figure 1E**). Peripheral blood of the *Vhl*KO mice showed decreased B cells at all ages examined, whereas monocytes were increased at 10-weeks-old, and granulocytes at 6-months-old only (**Supplemental Figure 1F**). Furthermore, we observed greater proportions of monocytes and granulocytes and an overall reduction in the absolute numbers of all hematopoietic lineages in the BM of *Vhl*KO mice (**Table 1**).

Increased frequencies of hematopoietic progenitor cells in the *Vhl*KO BM

To further investigate if the defect in hematopoiesis occurred upstream of lineage-committed cells, we analyzed the hematopoietic progenitor compartments in the BM of *Vhl*KO mice. Long-term hematopoietic stem cells (LT-HSCs: LSK, CD150⁺ CD48⁻, short term hematopoietic stem cells (ST-HSCs: LSK, CD150⁻, CD48⁻), multipotent progenitors (MPP2:

LSK, CD150⁺, CD48⁺; MPP3: LSK, CD150⁻, CD48⁺; and MPP4: LSK, CD150⁻, Flk2⁺, CD48⁺), and common lymphoid progenitors (CLPs: Lineage⁻, CD127⁺, cKIT^{int}, Sca1^{int}) from *Vhl*cKO and control mice were quantified using flow cytometry (**Figure 2A, B**). The results showed an increase in the frequency in LT-HSCs, ST-HSCs, MPP2, MPP3, and CLPs at 6-weeks, 10-weeks and 6-months-old (**Figure 2C**). MPPs are heterogeneous with different lineage-biased potential. MPP2/3 are myeloid-biased while MPP4 are lymphoid-primed (49, 50). In our results, MPP4 frequency was increased starting at 10-weeks-old (**Figure 2C**). These results show that deletion of *Vhl* in *Dmp1*-expressing cells increases progenitor frequencies and indicates that downstream differentiation of B cells may be blocked. However, examination of MPP4 absolute numbers showed decreased MPP4s in 6-week-old *Vhl*cKO, an increase at 10-weeks-old, and numbers similar to controls at 6-months old. In 10-week-old *Vhl*cKO mice, the absolute numbers of LT-HSCs and MPP3 were increased, whereas at 6-months-old, LT-HSCs and CLPs were decreased (**Figure 2D**).

***Vhl* deletion in *Dmp1*-expressing cells dysregulates B cell development in the BM**

To further explore the effects of *Vhl* deletion in OBs and OCYs on B cell development and to identify at which stage B cell development was stunted in the BM, we determined the frequencies of Hardy Fractions A-F (**Figure 3A, Supplemental Figure 2**) using flow cytometry (1, 51). A decrease in frequencies of Fractions B-C and Fraction F was observed as early as 6-weeks-old, and across Fractions B through Fractions F was observed at 10-weeks-old and 6-months-old (**Figure 3B**). An overall decrease in the absolute numbers of B cells across all developmental stages was observed at all three ages (**Figure 3C**). *Vhl*cKO mice regardless of age displayed increased CLPs, retained normal frequency of Fraction A, whereas later Fractions were

all decreased (**Figure 3B**). These results indicate an incomplete block in B cell development that starts at Fractions B-C in *Vhl*KO mice.

Reciprocal bone marrow transplantation studies reveal a cell-extrinsic effect of the *Vhl*KO microenvironment on B cell development

We expected the cause of the B cell defect to lie within the non-hematopoietic cells, since *Dmpl* is not expressed in hematopoietic cells. To definitively determine if the effects of *Vhl* deficiency on B lymphopoiesis were due to changes in the non-hematopoietic microenvironment within the bone, we performed whole BM transplants from WT (CD45.1+) donors into lethally irradiated *Vhl*KO (CD45.2+) recipients (WT→*Vhl*KO chimeras (**Figure 4A**)). Control WT (CD45.1+)→WT (CD45.2+) chimeras were also prepared. Donor hematopoietic chimerism was similar in controls and chimeras (**Figure 4B**). Analysis 16 weeks post-transplant showed a significant reduction in BM cellularity (**Figure 4C**) and an increase in granulocytes and monocytes, and a decrease in B cells in the WT→*Vhl*KO mice (**Figure 4D**). Analysis of B cells revealed a decrease at Fractions A through Fraction F in both frequency and absolute numbers (**Figure 4E, F**), similar to that observed in non-transplanted *Vhl*KO mice (**Figure 3**). In contrast, overall hematopoiesis, including B cell development, was normal in the *Vhl*KO→WT chimeras (**Supplemental Figure 3**). Since *Vhl* deletion in B cells can affect their function (52, 53), we confirmed that *Vhl* remained intact and was not erroneously deleted in B cells in our *Vhl*KO mice (**Supplemental Figure 4**). These results confirm a cell-extrinsic effect of the non-hematopoietic *Vhl*KO BM microenvironment on hematopoiesis.

***Vhlc*KO mice display patterns of reduced B cell proliferation and increased B cell apoptosis in the BM**

We hypothesized that the observed reduction of B cells was due to increased apoptosis and diminished B cell proliferation in the BM. To test this, B cells were stained with Annexin V and 7AAD to identify cells that were live, in early stage apoptosis or late stage apoptosis (**Figure 5A, left panels**). Normally, apoptosis is the most extensive in Fraction A (pre-pro-B cells) amongst the B cell fractions (54). The frequencies of *Vhlc*KO Fraction A cells in live, early and late apoptosis stages was comparable to controls at 6- and 10-weeks-old. However, at 6-months old, Fraction A comprised fewer live cells and more late apoptotic cells compared to controls. Apoptosis in Fraction B-C in *Vhlc*KOs was similar to controls at 6-weeks-old, but then displayed an increase in late apoptosis at 10-weeks-old and 6-months-old (**Figure 5B**). A reduction of live Fraction B-C cells was also observed at 6-months old (**Figure 5B**). No differences in the stages of apoptosis were observed between controls and *Vhlc*KOs for Fractions D, E and F (**Supplemental Figure 5**).

B cell development leads to the assembly and signaling of the B cell antigen receptor (BCR). CD43⁺ Fraction A-C (pre-pro-B and pro-B cells) normally have higher proliferation rates compared to CD43⁻ Fraction D-E (Pre-B cells and immature B cells) (5, 55). Proliferation is halted at Fraction D (small pre-B cell) to allow light (L) chain gene rearrangement, subsequently expressing a complete IgM surface molecule (Fraction E) (5, 56). Cell cycle analysis was performed using Ki67 and DAPI staining (**Figure 5A, right panels**). At 6-weeks-old, there were no differences in the distribution of cells in G0 (quiescent), G1, or S2/G2/M phases between *Vhlc*KO and control mice. However, at 10-weeks-old and 6-months-old, Fractions B-C contained a reduced percentage of cells in G1 and S/G2/M cell cycle phases, and an increased percentage in

G0 (**Figure 5C**). This indicates a reduced ability of early B cell progenitors to proliferate in a *Vhl*-deficient microenvironment. No difference in proliferation of Fractions D-F was observed at any age examined, with the exception of a slight (yet statistically significant) reduction of the *Vhl*cKO Fraction F cells in G0 and increase in G1 at 6-months-old (**Supplemental Figure 6**).

B cell development at each stage requires specific signaling molecules from a variety of niche cells (5, 57). To examine for changes in the distribution of niche cells in *Vhl*cKO bones, control and *Vhl*cKO long bones were digested and stained for stromal cell populations by flow cytometry (**Supplemental Figure 7**) (58, 59). Using this approach, the *Vhl*cKO mice displayed reduced frequency of ECs, while MSCs, and OBs remained similar to controls. To further explore the dysregulated niche, BM serum was analyzed for levels of CXCL12 and SCF, which are critical for B cell development (1, 24, 28, 29). CXCL12 levels were reduced in the *Vhl*cKO BM serum, while SCF levels were unaffected (**Figure 5D**). This suggested that increased apoptosis and reduced proliferation of Fraction B-C cells are caused by reduced CXCL12 levels and lack of ECs in the *Vhl*cKO BM.

Evidence for elevated oxygen levels in local niches in the *Vhl*cKO bone marrow

Hypoxic niches in the BM microenvironment are crucial for hematopoiesis development. Dynamic regulation of HIF-1 α levels are required for normal B cell development such that HIF activity is high in pro-B and pre-B cells and decreases in the immature B cell stage in the BM (60). In wild type mice, studies using the hypoxic marker pimonidazole (PIM) revealed that HSCs in the BM stain positively with PIM, indicating a hypoxic niche (61). To evaluate hypoxia in distinct B cell developmental stages, *Vhl*cKO and control mice were injected with PBS or 120 mg/kg PIM. PIM staining of LSKs in the BM stained positively for PIM, as previously reported by other groups

(**Figure 6A**). CD45⁺ B220⁺ cells (which include all Hardy Fractions, in addition to other hematopoietic progenitors, natural killer cells, dendritic cells and T cells (62-66)) displayed positive, yet less intense staining with PIM in both control or *VhlcKO* mice (**Figure 6A**). Normalization of PIM staining on LSK HSCs and CD45⁺ B220⁺ cells in four *VhlcKO* mice to the mean staining in controls showed no statistically significant differences (**Figure 6B**). However, examination of PIM staining in distinct Hardy Fractions revealed that in general, the early B cell progenitors (Fraction A) stain with PIM at a higher level than the mature B cells (Fraction F). Notably, *VhlcKO* mice displayed diminished intensity of PIM staining compared to control mice across all B cell fractions (**Figure 6C, Table 2**). This reveals that similar to LSKs, Fraction A cells might reside in a hypoxic niche, and as they mature they move away to a less hypoxic niche. Moreover, these data indicate that B cells in the *VhlcKO* BM may experience higher oxygen levels as compared to control mice in their local niches.

Increased bone marrow blood vessel diameter and density in *VhlcKO* microenvironments

To more precisely examine the changes in the microenvironment of *VhlcKO* mice, we imaged femurs that were shaved to remove cortical bone (for analysis of the metaphysis) or optically cleared with a modified uDISCO protocol (for analysis of the fully intact diaphysis) (**Supplemental Videos 1-2**) (43). We measured the vessel diameter and frequency in the cleared long bones and found that regardless of their position in the BM, blood vessels in *VhlcKO* mice were significantly larger than the control group (**Figure 7A-C**) while generally no difference was observed in the vessel frequency (**Supplemental Figure 8A**). Bone and BM vessel density measurements in both the metaphysis and diaphysis revealed that in *VhlcKO*, blood vessels occupy a larger volume than controls (**Figure 7D-F, Supplemental Figure 8B-C**). Furthermore, we

observed an apparent decrease in endosteal lining arterioles in the diaphysis of 6-month-old *VhlcKO* femurs compared to controls (**Supplemental Figure 8D**). Taken together, these data reveal a striking alteration in the overall architecture of the BM vascular network in *VhlcKO* mice.

***VhlcKO* bone marrow blood vessels display increased permeability**

While it has been shown that the bone and vascular system undergoes significant remodeling in *VhlcKO* mice, there has been a lack of information regarding potential functional changes to BM blood vessels. To examine changes to the BM vasculature system which could negatively impact B cell development, we sought to quantify changes to the vascular permeability, leakage and blood flow velocity via intravital two-photon microscopy of the calvaria. Vessel permeability reflects the rate at which small molecules exit blood vessels and fill the surrounding perivascular space, whereas leakage is the ratio of fluorescent dye in the perivascular space and vascular lumen after reaching equilibrium. Blood vessel leakage and permeability was calculated by administering Rhodamine B Dextran (70kDa) via a retro-orbital injection. We found that *VhlcKO* mice displayed greater vascular leakage overall, and that vascular leakage increased in both control and *VhlcKO* mice with age (**Figure 8A-B, Supplemental Videos 3-8**). Similarly, we observed an increase in vascular permeability in *VhlcKO* mice, which significantly increased with age (**Figure 8C, Supplemental Video 9-10**). We observed a decrease in blood flow velocity in *VhlcKO* mice compared to controls for 6-week-old and 10-week-old mice (**Figure 8D**). Lastly, we observed an age-related reduction in blood flow in both *VhlcKO* and control mice (**Figure 8D**), which is consistent with previously published changes in BM vascular flow rate with age (67).

DISCUSSION

VHL plays an important role regulating HIF expression, and disruption of *Vhl* in bone cells leads to improper bone homeostasis (7, 8, 19, 37). *Vhl* deletion in osteochondral progenitor cells and osteocalcin-positive OBs leads to an increase in bone mass through an increase in OB number (7, 19). Furthermore, disrupting VHL in OBs induces expression of β -catenin, revealing that VHL/HIF pathway promotes bone formation through the Wnt pathway (7, 20, 21). Altogether, these studies of *Vhl* deletion in osteolineage cells have not examined the cell-extrinsic effects of these changes on the immune cells residing in the BM. In this report, we establish that deletion of *Vhl* in late OBs and OCYs results in cell-extrinsic changes that does not support full development and survival of B cells.

BM stromal cells include a variety of non-hematopoietic cells, such MSCs and OBs, which are the precursors of mature mineralized OCYs, and ECs. All of these cells support B cell development (1, 28, 31, 32). In our study, using flow cytometry after bone digest, we found that the distribution of the stromal cell populations was not affected in the *Vhl*cKO, with the exception of CD31+ ECs, which were reduced. This was surprising due to the increase in vessel volume and number that was observed in the ex vivo imaging of *Vhl*cKO long bones. The differences in the results may reflect a limitation in the bone digestion protocol that is used for analyzing BMSCs by flow cytometry. It is widely accepted that with this protocol, hematopoietic cells, likely from the bone marrow, are still evident after rinsing of the bone chips and collagenase digestion. Therefore, we cannot determine if the ECs examined are residual BM ECs or resident bone ECs. In addition, the increased density of *Vhl*cKO bone makes it challenging to digest completely and all of the ECs from the bone may not be released. Given this caveat, we believe that our imaging results are more accurate than the flow cytometry, and the imaging results suggest that there is an increase in bone ECs, which is consistent with previous studies in *Osx-Cre;Vhl^{fl/fl}* mice where endomucin staining

showed that *Vhl* deletion increased bone vasculature with dilated blood vessels (37). We also observed larger vessels in the BM across all ages and an increase in BM blood volume. These changes, along with the observed decrease in endosteal arterioles in the long bones, suggests that oxygenation of the *Vhl*KO marrow may be higher than normal, which may play a role in dysregulation of B cell development. Future studies will be needed to clarify this and to identify other changes in specific types or locations of blood vessels in the *Vhl*KO model.

Given the connection between *Vhl* and hypoxia response, it was interesting that EPO levels were high in the BM serum of the *Vhl*KO mice. This has been confirmed in other studies, where deletion of *Vhl* at the mature OB stage using the *Osx*-Cre and *Ocn*-Cre (targeting osteoprogenitors) (8, 19, 20) and at the late OB/OCY stage using *Dmp*-Cre increased bone mass and angiogenesis, likely through HIF1 α -regulated expression of VEGF and EPO. If the elevated EPO levels directly affect B cell development in the *Vhl*KO BM has not yet been verified. However, it has been reported that ECs in the BM suppress levels of CXCL12 expression in response to increased EPO levels (68). We also observed decreased CXCL12 in the BM sera of *Vhl*KO mice. CXCL12 is required for proper development and retention of B cells in the BM (32, 69). This suggests that altered vascular components in the *Vhl*KO bone and BM microenvironments impair B cell development possibly through the effects of EPO on EC function.

Permeability of the BM vasculature in the *Vhl*KO mice was also compromised. We found an increased vascular leakage and permeability in the *Vhl*KO BM compared to controls regardless of age. In addition, vascular permeability appeared to increase with age, with the highest vascular permeability and leakage being observed in 6-month-old *Vhl*KO mice when compared with 6-week-old mice. Interestingly, it was observed that vascular blood flow velocity decreased in 6-week-old and 10-week-old *Vhl*KO mice but was not affected in 6-month-old *Vhl*KO mice. An

increase in blood flow velocity would normally explain an increase in permeability and leakage, but that is not evident in our data. Instead, the more likely explanation is that the blood-bone marrow barrier is compromised, increasing the exposure of the BM to plasma components.

Deletion of *Vhl* in B cells stabilizes *Hif1α* levels and affects mature B cell function by impairing cell proliferation, antibody class-switching, generation of high affinity antibodies, antibody responses, and impairs metabolic balance essential for naive B cell survival and development (52, 53, 70). Dynamic regulation of HIF-1α levels was also found to be a crucial step in B cell development in the BM (60). Burrows et al. found decreased *Hif1α* activity at the immature B cell stage in the BM and that HIF-1α suppression was required for normal B cell development (60). This dynamic regulation of HIF-1α activity during B cell development is consistent with our results, which revealed that Fraction A cells stain highly with PIM, and PIM staining was reduced as B cell development progressed to Fraction F. Together, our findings and that of Burrows et al. suggest that the earliest B cell stages (e.g. pre-pro B, Fraction A) might prefer a more hypoxic niche compared to the later B cell stages. We also found that the *Vhl*cKO mice displayed lower intensity of PIM staining on B cells compared to controls, suggesting a hyperoxic state, which could also be deleterious for B cell development. Although *Vhl* is deleted in OBs and OCYs in our model, we cannot yet rule out if this deletion is artificially causing changes that would be found in a true hypoxic state through *Hif1* stabilization, when in fact the oxygenation of the BM of the *Vhl*cKO is not altered. In addition, PIM cannot provide true quantification of dissolved oxygen concentration in tissue. PIM adduct staining results could reflect inadequate oxygen supply to the BM, faulty rates of intracellular oxygen consumption, or both. Direct in vivo measurement of oxygen tension using two-photon phosphorescence lifetime microscopy would help answer this question (11).

HSCs were increased in previous studies that showed that HSCs can maintain cell cycle quiescence and function through regulation of HIF-1 α levels (9). In our studies, we found that HSCs and upstream progenitors of B cells were increased in frequency. We found that the increase in progenitors is due to the inability to mature into B cells, but it remains unclear whether there is a shift from lymphoid to myeloid skewing. Some possible studies to sort out lineage bias would be through immune phenotyping analysis such as single cell sequencing to explore expression signatures (myeloid vs. lymphoid) to reveal lineage fate (49) or limiting dilution analysis and single cell transplantation as previously done by other groups to show the ratio of myeloid to lymphoid cell output (71-74).

The information generated in this study helps define the role of *Vhl* and altered bone homeostasis on immune cell development. Our results suggest the following working model of the interactions in the BM microenvironment that controls B cell development (**Figure 9**): *Vhl* in OCYs and late OBs play a significant role in the BM microenvironment, indirectly regulating B cell development through a decrease in CXCL12, an increase in EPO, increased vasculature and vascular permeability. However, oxygen tension in the niche of early stage B cell fractions is yet to be determined. Our results demonstrate the significant changes of the physical niche in *Vhl*CKO mice and their effects on B cell development. Whether the physical space, niche cells, or molecular signals all play a direct or indirect role on B cell development remains to be explored and defined, with the possibility that these events are completely independent of each other. The results of this work could contribute to the development of new therapies or new targets for exogenous CXCL12 and EPO antagonists, to preserve and improve bone marrow function during microenvironmental niche changes or stress.

ACKNOWLEDGMENTS

We thank the staff of the Department of Animal Research Services (DARS) and the Stem Cell Instrumentation Foundry (SCIF) at UC Merced for the excellent animal care and technical support. We also acknowledge Hawa Padmore and William Pratcher for their early contributions to protocol setup. The authors also thank the staff of the Health Sciences Research Institute (HSRI) at UC Merced for their administrative support. This work was funded by the University of California, NIH grants R15 AI154245-01 (J.O.M. and J.A.S.) and NIH F31 AI154815 (B.C.), and through support of the NSF-CREST: Center for Cellular and Biomolecular Machines at the University of California, Merced (NSF-HRD-1547848; N.A., C.B., and J.A.S.).

REFERENCES

1. T. Nagasawa, Microenvironmental niches in the bone marrow required for B-cell development. *Nat Rev Immunol* **6**, 107-116 (2006).
2. J. O. Manilay, M. Zouali, Tight relationships between B lymphocytes and the skeletal system. *Trends Mol Med* **20**, 405-412 (2014).
3. C. Panaroni, J. Y. Wu, Interactions between B lymphocytes and the osteoblast lineage in bone marrow. *Calcif Tissue Int* **93**, 261-268 (2013).
4. M. Aurrand-Lions, S. J. C. Mancini, Murine Bone Marrow Niches from Hematopoietic Stem Cells to B Cells. *Int J Mol Sci* **19** (2018).
5. R. Carsetti, The development of B cells in the bone marrow is controlled by the balance between cell-autonomous mechanisms and signals from the microenvironment. *J Exp Med* **191**, 5-8 (2000).
6. V. H. Haase, The VHL tumor suppressor: master regulator of HIF. *Current pharmaceutical design* **15**, 3895-3903 (2009).
7. Y. Wang *et al.*, The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. *J Clin Invest* **117**, 1616-1626 (2007).
8. N. Dirckx *et al.*, Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism. *J Clin Invest* **128**, 1087-1105 (2018).
9. K. Takubo *et al.*, Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. *Cell Stem Cell* **7**, 391-402 (2010).
10. H. L. Bader, T. Hsu, Systemic VHL gene functions and the VHL disease. *FEBS Lett* **586**, 1562-1569 (2012).
11. J. A. Spencer *et al.*, Direct measurement of local oxygen concentration in the bone marrow of live animals. *Nature* **508**, 269-273 (2014).
12. M. Hirao *et al.*, Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. *J Bone Miner Metab* **25**, 266-276 (2007).
13. H. J. Knowles, Hypoxic regulation of osteoclast differentiation and bone resorption activity. *Hypoxia (Auckl)* **3**, 73-82 (2015).
14. D. E. Komatsu, M. Hadjiargyrou, Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. *Bone* **34**, 680-688 (2004).
15. A. Danis, [Mechanism of bone lengthening by the Ilizarov technique]. *Bull Mem Acad R Med Belg* **156**, 107-112 (2001).
16. Q. Zhao *et al.*, Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. *Bone* **50**, 763-770 (2012).
17. T. Tando *et al.*, Hif1alpha is required for osteoclast activation and bone loss in male osteoporosis. *Biochem Biophys Res Commun* **470**, 391-396 (2016).
18. Y. Miyauchi *et al.*, HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. *Proc Natl Acad Sci U S A* **110**, 16568-16573 (2013).
19. T. Weng *et al.*, Inactivation of Vhl in osteochondral progenitor cells causes high bone mass phenotype and protects against age-related bone loss in adult mice. *J Bone Miner Res* **29**, 820-829 (2014).
20. G. L. Zuo *et al.*, Activation of HIFa pathway in mature osteoblasts disrupts the integrity of the osteocyte/canalicular network. *PloS one* **10**, e0121266 (2015).
21. C. Wan *et al.*, Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. *Proc Natl Acad Sci U S A* **105**, 686-691 (2008).
22. W. C. Dougall *et al.*, RANK is essential for osteoclast and lymph node development. *Genes Dev* **13**, 2412-2424 (1999).
23. E. Sitnicka *et al.*, Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesis. *J Exp Med* **198**, 1495-1506 (2003).

24. I. K. McNiece, K. E. Langley, K. M. Zsebo, The role of recombinant stem cell factor in early B cell development. Synergistic interaction with IL-7. *J Immunol* **146**, 3785-3790 (1991).
25. C. Waskow, S. Paul, C. Haller, M. Gassmann, H. R. Rodewald, Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. *Immunity* **17**, 277-288 (2002).
26. U. von Freeden-Jeffry *et al.*, Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. *J Exp Med* **181**, 1519-1526 (1995).
27. S. Dias, H. Silva, Jr., A. Cumano, P. Vieira, Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. *J Exp Med* **201**, 971-979 (2005).
28. T. Egawa *et al.*, The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. *Immunity* **15**, 323-334 (2001).
29. T. Nagasawa *et al.*, Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* **382**, 635-638 (1996).
30. Y. Y. Kong *et al.*, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* **397**, 315-323 (1999).
31. A. C. Green *et al.*, The characterization of distinct populations of murine skeletal cells that have different roles in B lymphopoiesis. *Blood* 10.1182/blood.2020005865 (2021).
32. K. Tokoyoda, T. Egawa, T. Sugiyama, B. I. Choi, T. Nagasawa, Cellular niches controlling B lymphocyte behavior within bone marrow during development. *Immunity* **20**, 707-718 (2004).
33. A. Cariappa *et al.*, Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. *Immunity* **23**, 397-407 (2005).
34. J. A. Alberts B, Lewis J, et al., Blood Vessels and Endothelial Cells. *Molecular Biology of the Cell. 4th edition* (2002).
35. Z. Ungvari *et al.*, Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. *Nat Rev Cardiol* **15**, 555-565 (2018).
36. R. Oakley, B. Tharakan, Vascular hyperpermeability and aging. *Aging Dis* **5**, 114-125 (2014).
37. G. G. Loots *et al.*, Vhl deficiency in osteocytes produces high bone mass and hematopoietic defects. *Bone* **116**, 307-314 (2018).
38. F. Faul, E. Erdfelder, A. G. Lang, A. Buchner, G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* **39**, 175-191 (2007).
39. Y. Lu *et al.*, DMP1-targeted Cre expression in odontoblasts and osteocytes. *J Dent Res* **86**, 320-325 (2007).
40. V. H. Haase, J. N. Glickman, M. Socolovsky, R. Jaenisch, Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. *Proc Natl Acad Sci U S A* **98**, 1583-1588 (2001).
41. C. J. Cain *et al.*, Absence of sclerostin adversely affects B-cell survival. *J Bone Miner Res* **27**, 1451-1461 (2012).
42. D. M. Gravano, J. O. Manilay, Inhibition of proteolysis of Delta-like-1 does not promote or reduce T-cell developmental potential. *Immunol Cell Biol* **88**, 746-753 (2010).
43. C. Pan *et al.*, Shrinkage-mediated imaging of entire organs and organisms using uDISCO. *Nat Methods* **13**, 859-867 (2016).
44. D. A. Sipkins *et al.*, In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. *Nature* **435**, 969-973 (2005).
45. T. Itkin *et al.*, Distinct bone marrow blood vessels differentially regulate haematopoiesis. *Nature* **532**, 323-328 (2016).
46. Y. Jung *et al.*, Intravital Imaging of Mouse Bone Marrow: Hemodynamics and Vascular Permeability. *Methods Mol Biol* **1763**, 11-22 (2018).
47. T. N. Kim *et al.*, Line-scanning particle image velocimetry: an optical approach for quantifying a wide range of blood flow speeds in live animals. *PLoS One* **7**, e38590 (2012).
48. J. W. Wu *et al.*, Intravital fluorescence microscopy with negative contrast. *PLoS One* **16**, e0255204 (2021).

49. E. M. Pietras *et al.*, Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. *Cell Stem Cell* **17**, 35-46 (2015).
50. H. Cheng, Z. Zheng, T. Cheng, New paradigms on hematopoietic stem cell differentiation. *Protein & Cell* **11**, 34-44 (2019).
51. R. R. Hardy, C. E. Carmack, S. A. Shinton, J. D. Kemp, K. Hayakawa, Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. *J Exp Med* **173**, 1213-1225 (1991).
52. S. H. Cho *et al.*, Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system. *Nature* **537**, 234-238 (2016).
53. S. Xu *et al.*, von Hippel-Lindau Protein Maintains Metabolic Balance to Regulate the Survival of Naive B Lymphocytes. *iScience* **17**, 379-392 (2019).
54. L. W. Lu, D. G. Osmond, Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow. *Immunol Rev* **175**, 158-174 (2000).
55. H. J. Markus Werner, Chapter 6 - Proliferation and Differentiation Programs of Developing B Cells. *Molecular Biology of B Cells (Second Edition)* <https://doi.org/10.1016/B978-0-12-397933-9.00006-0>, 75-97 (2015).
56. A. Rolink, D. Haasner, F. Melchers, J. Andersson, The surrogate light chain in mouse B-cell development. *Int Rev Immunol* **13**, 341-356 (1996).
57. F. Melchers, Checkpoints that control B cell development. *J Clin Invest* **125**, 2203-2210 (2015).
58. K. Schepers, E. C. Hsiao, T. Garg, M. J. Scott, E. Passegue, Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. *Blood* **120**, 3425-3435 (2012).
59. I. G. Winkler *et al.*, Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. *Blood* **116**, 375-385 (2010).
60. N. Burrows *et al.*, Dynamic regulation of hypoxia-inducible factor-1alpha activity is essential for normal B cell development. *Nat Immunol* **21**, 1408-1420 (2020).
61. K. Parmar, P. Mauch, J. A. Vergilio, R. Sackstein, J. D. Down, Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. *Proc Natl Acad Sci U S A* **104**, 5431-5436 (2007).
62. A. Rolink *et al.*, A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. *J Exp Med* **183**, 187-194 (1996).
63. G. Balciunaite, R. Ceredig, S. Massa, A. G. Rolink, A B220+ CD117+ CD19- hematopoietic progenitor with potent lymphoid and myeloid developmental potential. *Eur J Immunol* **35**, 2019-2030 (2005).
64. T. Nikolic, G. M. Dingjan, P. J. M. Leenen, R. W. Hendriks, A subfraction of B220+ cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. *European Journal of Immunology* **32** (2002).
65. A. L. Blasius, W. Barchet, M. Cella, M. Colonna, Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. *J Exp Med* **204**, 2561-2568 (2007).
66. R. R. Hardy, P. W. Kincade, K. Dorshkind, The protean nature of cells in the B lymphocyte lineage. *Immunity* **26**, 703-714 (2007).
67. K. Kita, K. Kawai, K. Hirohata, Changes in bone marrow blood flow with aging. *J Orthop Res* **5**, 569-575 (1987).
68. T. Ito, Y. Hamazaki, A. Takaori-Kondo, N. Minato, Bone Marrow Endothelial Cells Induce Immature and Mature B Cell Egress in Response to Erythropoietin. *Cell Struct Funct* **42**, 149-157 (2017).
69. A. Greenbaum *et al.*, CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature* **495**, 227-230 (2013).

70. H. Kojima *et al.*, Differentiation stage-specific requirement in hypoxia-inducible factor-1 alpha-regulated glycolytic pathway during murine B cell development in bone marrow. *J Immunol* **184**, 154-163 (2010).
71. C. Benz *et al.*, Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. *Cell Stem Cell* **10**, 273-283 (2012).
72. B. Dykstra *et al.*, Long-term propagation of distinct hematopoietic differentiation programs in vivo. *Cell Stem Cell* **1**, 218-229 (2007).
73. C. E. Muller-Sieburg, R. H. Cho, L. Karlsson, J. F. Huang, H. B. Sieburg, Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. *Blood* **103**, 4111-4118 (2004).
74. C. E. Müller-Sieburg, R. H. Cho, M. Thoman, B. Adkins, H. B. Sieburg, Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. *Blood* **100**, 1302-1309 (2002).
75. T. A. Shih, M. Roederer, M. C. Nussenzweig, Role of antigen receptor affinity in T cell-independent antibody responses in vivo. *Nat Immunol* **3**, 399-406 (2002).

Figure 1. Bone marrow, spleen and peripheral blood lineage cell defects in the *VhlcKO* mice. A) Macroscopic and ex vivo imaging of the long bones revealed progressive increases in the bone mass in *VhlcKO* femurs compared with the controls. Inset: photo of the femur. Red: blood vessel (AlexaFluor647 CD31, AlexaFluor647 CD144, AlexaFluor647 Sca-1), Blue: bone (SHG). Scale bar ~100µm; B) bone marrow cellularity, C) representative FACS plots of immune cell lineages; D) frequency analysis of bone marrow lineage cells at 6-weeks of age (left), 10-weeks of age (middle) and 6-month (right). $p < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$ two-tailed Student's t-test.

Figure 2. Altered B cell development in WT→*Vhl*KO hematopoietic chimeras, demonstrating a cell-extrinsic effect of *Vhl*-deleted osteolineage cells on B cell development. A) Representative FACS plots of common lymphoid progenitors (CD127⁺ Sca1^{int} cKit^{int}); B) representative FACS plots of hematopoietic progenitors in the bone marrow of controls (top) and *Vhl*KOs (bottom); C) frequency and D) absolute number of hematopoietic progenitors in the bone marrow in 6-weeks-old (left), 10-weeks-old (middle) and 6-months-old (right) mice. $p < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$ two-tailed Student's t-test.

Figure 3. Dysregulated B cell development in *VhlcKO* mice bone marrow. A) Representative FACS plot of B cell development in the BM control (top) and *VhlcKO* (bottom); B) B cell frequency in 6-week-old (left), 10-week-old (middle), and 6-month-old (right) mice; C) absolute cell numbers in 6-week-old (left), 10-week-old (middle), and 6-month-old (right). $p < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$ two-tailed Student's t-test.

Figure 4. Altered B cell development in WT→*Vhlc*KO hematopoietic chimeras demonstrates a cell-extrinsic effect of the *Vhlc*KO bone on B cell development. Mice were transplanted at 10 weeks of age and were analyzed 16 weeks post-transplantation. A) experimental scheme; B) donor (CD45.1) chimerism; C) bone marrow cellularity; D) frequency of lineage cells in bone marrow; E) B cell frequency and F) absolute number of B cell developmental stages at 16 weeks post-transplant. $p < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$ two-tailed Student's t-test.

Figure 5. *VhlcKO* mice display increase apoptosis and reduced cell proliferation during early B cell development. A) Representative FACS plots of apoptotic phases in B220+ cells (left) and cell cycle phases in B220+ cells (red:CD43+ blue: CD43-) (right); B) frequency of apoptotic phases in Fractions A and B-C in 6-weeks-old, 10-weeks-old and 6-month-old mice; C) frequency of cells in each cell cycle phase within Fractions A and B-C at 6-weeks-old, 10-weeks-old and 6-month-old mice; D) CXCL12, SCF, TPO, and EPO cytokine level measurements in bone marrow serum of control or *VhlcKO* mice. $p < 0.05$ *, $p < 0.01$ **, $p < 0.001$ ***, $p < 0.0001$ **** two-tailed Student's t-test.

Figure 7. Ex vivo two-photon imaging of long bones in *VhlckKO* and controls. A) Representative macroscopic images of the femur diaphyseal BM (scale bars: ~200 μm), B) magnified z-stacks (scale bars: ~100 μm), and C) statistical analysis after uDISCO clearing show an increase in the *VhlckKO* vascular diameter relative to the controls; D) *ex vivo* images of femur metaphyseal BM after max intensity projection reveal bone replacement and vascular alteration in *VhlckKO*; E-F) quantification of the metaphyseal and diaphyseal vascular density (scale bars: ~200 μm). Red: blood vessels (labeled with Alexa647 conjugated antibodies against CD31, CD144, and Sca-1), Blue: bone (SHG: Second harmonic generation). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, two-tailed Student's t-test.

Figure 8. Disruption in blood-bone marrow barrier revealed by intravital microscopy. Blood vessel microenvironment comparisons of control and *VhlckO* mice at 6-week (n=4), 10-week (n=4) and 6-month (n=5) timepoints. A) Representative contrast adjusted max intensity projections of the calvarial BM in control and *VhlckO* mice by age; White: blood vessel (Rhodamine B Dextran, 70 kDa); scale bar: 50 μ m; quantification of calvarial BM B) blood vessel leakage, C) vascular permeability, and D) blood flow velocity. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, Mann-Whitney test.

Figure 9. Working model describing the changes in the bone marrow microenvironment in *VhlcKO* mice. Left panel: Schematic of healthy control bone marrow where VHL/HIF signaling is intact, the transition from osteoblasts to osteocytes is homeostatically balanced and interactions of developing B cells and stromal cells within their niches promotes their differentiation, maturation and proliferation. Right panel: Lack of *Vhl* in late osteoblasts and osteocytes has a severe effect on hematopoiesis in the bone marrow, changing the B cell niche and indirectly regulating B cell development through decrease of CXCL12, increase of EPO and changes to the BM microenvironment vasculature and permeability. Direct measurement of pO_2 in the BM is necessary to determine if the BM oxygenation landscape is altered compared to controls.

Table 1. Hematopoietic lineage mean $\pm$ SD and absolute number $p < 0.05^*$, $p < 0.01^{}$, $p < 0.001^{***}$, $p < 0.0001^{****}$ two-tailed Student's t-test.**

Lineage Population	CD45+ population (mean% $\pm$ SD)				Absolute Number (mean $\pm$ SD)			
	Bone Marrow		Spleen		Bone Marrow		Spleen	
6 weeks old	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO
B cells	44.16 $\pm$ 7.16	33.69 $\pm$ 8.49**	60.71 $\pm$ 2.64	58.57 $\pm$ 3.51	2.62E+0.7 $\pm$ 7.06E+06	8.88E+0.6 $\pm$ 4.83E+06****	6.35E+0.7 $\pm$ 1.28E+07	5.71E+0.7 $\pm$ 9.18E+06
T cells	1.45 $\pm$ 0.79	1.61 $\pm$ 0.62	23.65 $\pm$ 3.56	23.49 $\pm$ 3.42	8.36E+0.5 $\pm$ 4.33E+05	3.70E+0.5 $\pm$ 1.87E+05***	2.49E+0.7 $\pm$ 6.57E+06	2.29E+0.7 $\pm$ 4.93E+06
Monocytes	2.58 $\pm$ 0.37	3.28 $\pm$ 0.74**	2.55 $\pm$ 0.57	1.95 $\pm$ 0.15**	1.53E+0.6 $\pm$ 3.92E+05	7.81E+0.5 $\pm$ 3.48E+05****	2.66E+0.6 $\pm$ 7.87E+05	1.90E+0.6 $\pm$ 2.96E+05*
Granulocytes	38.46 $\pm$ 7.61	44.85 $\pm$ 6.47*	2.85 $\pm$ 2.55	2.28 $\pm$ 0.66	2.42E+0.7 $\pm$ 1.12E+07	1.06E+0.7 $\pm$ 4.30E+06***	2.71E+0.6 $\pm$ 2.19E+06	2.17E+0.6 $\pm$ 5.06E+05
10 weeks old	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO
B cells	33.8 $\pm$ 4.55	15.83 $\pm$ 7.01****	60.71 $\pm$ 7.63	46.37 $\pm$ 7.53****	3.32E+0.7 $\pm$ 1.47E+07	8.02E+0.6 $\pm$ 1.29E+07***	1.22E+08 $\pm$ 6.02E+07	1.18E+08 $\pm$ 5.98E+07
T cells	2.34 $\pm$ 1.04	2.35 $\pm$ 0.95	26.67 $\pm$ 6.15	29.09 $\pm$ 4.11	2.55E+0.6 $\pm$ 1.92E+06	1.05E+0.6 $\pm$ 1.35E+06*	6.22E+07 $\pm$ 5.28E+07	8.10E+07 $\pm$ 5.40E+07
Monocytes	4.09 $\pm$ 0.67	6.23 $\pm$ 1.25****	2.50 $\pm$ 0.36	2.71 $\pm$ 0.38	4.08E+0.6 $\pm$ 2.08E+06	2.41E+0.6 $\pm$ 1.89E+06*	5.49E+06 $\pm$ 4.12E+06	7.02E+06 $\pm$ 3.81E+06
Granulocytes	45.93 $\pm$ 6.89	58.11 $\pm$ 7.78***	1.15 $\pm$ 0.50	6.27 $\pm$ 2.93****	4.36E+0.7 $\pm$ 1.60E+07	2.22E+0.7 $\pm$ 1.50E+07**	2.14E+06 $\pm$ 9.96E+05	1.66E+07 $\pm$ 1.46E+07**
6 months old	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO	Control	<i>Vhl</i> cKO
B cells	25.74 $\pm$ 7.62	8.37 $\pm$ 1.76****	61.38 $\pm$ 7.09	42.44 $\pm$ 3.65****	1.48E+0.7 $\pm$ 7.35E+06	9.73E+0.5 $\pm$ 2.56E+05****	4.33E+0.7 $\pm$ 2.04E+07	2.77E+0.7 $\pm$ 7.48E+06**
T cells	2.21 $\pm$ 0.62	2.23 $\pm$ 0.38	25.55 $\pm$ 2.81	25.88 $\pm$ 2.68	1.20E+0.6 $\pm$ 5.48E+05	2.58E+0.5 $\pm$ 5.65E+04****	1.66E+0.7 $\pm$ 6.08E+06	1.70E+0.7 $\pm$ 5.08E+06
Monocytes	3.57 $\pm$ 1.31	5.98 $\pm$ 1.69****	1.82 $\pm$ 0.47	2.60 $\pm$ 0.67***	1.94E+0.6 $\pm$ 9.20E+05	6.97E+0.5 $\pm$ 2.28E+05****	1.19E+0.6 $\pm$ 3.95E+05	1.74E+0.6 $\pm$ 7.95E+05*
Granulocytes	56.01 $\pm$ 7.91	69.31 $\pm$ 3.49****	2.83 $\pm$ 4.41	14.33 $\pm$ 3.33****	3.08E+0.7 $\pm$ 1.26E+07	8.22E+0.6 $\pm$ 2.11E+06****	1.64E+0.6 $\pm$ 2.16E+06	9.52E+0.6 $\pm$ 3.42E+06****

Table 2. Mode Fluorescence Intensity of PIM staining on B cell fractions in control and *Vhl* cKO

Genotype	Treatment	MFI (mode)				
		Fr A	Fr B-C	Fr D	Fr E	Fr F
<i>Vhl</i> cKO	Isotype	336	125	146	187	146
<i>Vhl</i> cKO	Isotype	358	166	166	166	208
Control	PIM	3561	742	588	663	613
Control	PIM	3234	769	663	663	689
Control	PIM	2292	493	470	470	402
Control	PIM	3926	769	715	663	663
<i>Vhl</i> cKO	PIM	2514	493	402	336	424
<i>Vhl</i> cKO	PIM	2593	613	516	540	588
<i>Vhl</i> cKO	PIM	3926	689	570	663	564
<i>Vhl</i> cKO	PIM	3561	588	516	493	516